Cordis

Motus GI Announces Executive Leadership Restructuring and Additional Cost Saving Initiatives to Support Near-Term Milestones

Retrieved on: 
Thursday, April 13, 2023

As part of the executive changes, Mr. Moran has elected to step down as Chief Executive Officer (CEO) of the Company to pursue other business opportunities.

Key Points: 
  • As part of the executive changes, Mr. Moran has elected to step down as Chief Executive Officer (CEO) of the Company to pursue other business opportunities.
  • Mr. Moran will work closely with Mr. Pomeranz to support a smooth transition and maintain key relationships with Motus GI’s stakeholders.
  • To help ensure adequate financial resources are available to the Company, Motus GI has implemented additional cost-cutting measures to aggressively preserve capital.
  • The cost reduction measures announced today are in addition to the strategic restructuring program announced in January 2023.

InspireMD Announces Hiring of Medical Device Commercial Veteran Shane Gleason as General Manager of North America and VP of Global Marketing

Retrieved on: 
Tuesday, February 14, 2023

TEL AVIV, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that it has hired medical device commercial veteran Shane Gleason as General Manager of North America and Vice President of Global Marketing.

Key Points: 
  • TEL AVIV, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that it has hired medical device commercial veteran Shane Gleason as General Manager of North America and Vice President of Global Marketing.
  • Mr. Gleason brings to InspireMD significant expertise in vascular interventions and a track record of successful go-to-market execution.
  • His knowledge of the carotid market, reputation with our key opinion leader (KOL) partners and track record of successfully executing new product launches globally add tremendous capabilities to our senior team.
  • Earlier in his career, Mr. Gleason held sales and marketing leadership roles at Cordis, a Cardinal Health company, Trivascular Technologies (part of Endologix), and Abbott Vascular, where he launched the second FDA approved carotid stent system.

Orchestra BioMed Strengthens Senior Leadership Team

Retrieved on: 
Tuesday, February 7, 2023

NEW HOPE, Pa., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the addition of several highly accomplished industry veterans to its senior leadership team. Avi Fischer, M.D., joins as Senior Vice President (SVP), Medical Affairs and Innovation, and J.C. Simeon assumes the role of SVP, Quality. George Papandreou, Ph.D., has been promoted to General Manager and SVP of Focal Therapies (previously SVP, Quality) and Kunal Faldu has been promoted to Vice President (VP) of Pharmaceutical Development (previously Senior Director, Formulation Development).

Key Points: 
  • “We are very pleased to have several outstanding industry leaders join and assume key roles on our leadership team.
  • George and Kunal have proven themselves as important leaders within our growing organization,” said Darren R. Sherman, President, Chief Operating Officer and Co-Founder of Orchestra BioMed.
  • Prior to joining Orchestra BioMed, he held senior roles at C.R.
  • Before joining Orchestra BioMed, Mr. Faldu worked for Solaris Pharma Corporation as Senior Director, Program Management and Manufacturing.

Use of ETQ Reliance Quality Management System Expanded Across the U.S. and Internationally in 2022

Retrieved on: 
Wednesday, January 4, 2023

BURLINGTON, Mass., Jan. 4, 2023 /PRNewswire/ -- ETQ, part of Hexagon, today announced a year of significant growth and international expansion, fueled by its acquisition by and ongoing integration with Hexagon. This year the company also enhanced the functionality of Reliance NXG with new applications and other improvements to the industry's most robust, cloud-native quality management system (QMS). 

Key Points: 
  • This year the company also enhanced the functionality of Reliance NXG with new applications and other improvements to the industry's most robust, cloud-native quality management system (QMS).
  • "This has been one of the most exciting years of growth, expansion and opportunity for ETQ," said Rob Gremley, CEO, ETQ.
  • Hexagon, a global leader in digital reality solutions combining sensor, software and autonomous technologies, completed its acquisition of ETQ in 2022.
  • Additionally, a host of current quality-driven customers expanded their use of ETQ Reliance in their quality and safety programs.

Use of ETQ Reliance Quality Management System Expanded Across the U.S. and Internationally in 2022

Retrieved on: 
Wednesday, January 4, 2023

BURLINGTON, Mass., Jan. 4, 2023 /PRNewswire/ -- ETQ, part of Hexagon, today announced a year of significant growth and international expansion, fueled by its acquisition by and ongoing integration with Hexagon. This year the company also enhanced the functionality of Reliance NXG with new applications and other improvements to the industry's most robust, cloud-native quality management system (QMS). 

Key Points: 
  • This year the company also enhanced the functionality of Reliance NXG with new applications and other improvements to the industry's most robust, cloud-native quality management system (QMS).
  • "This has been one of the most exciting years of growth, expansion and opportunity for ETQ," said Rob Gremley, CEO, ETQ.
  • Hexagon, a global leader in digital reality solutions combining sensor, software and autonomous technologies, completed its acquisition of ETQ in 2022.
  • Additionally, a host of current quality-driven customers expanded their use of ETQ Reliance in their quality and safety programs.

Aron Ain, Former UKG CEO, to Join Hellman & Friedman as Operating Partner

Retrieved on: 
Thursday, December 8, 2022

Hellman & Friedman (H&F), a premier global private equity firm, today announced that Aron Ain is joining the firm in an advisory role as an Operating Partner and member of the H&F CEO Council.

Key Points: 
  • Hellman & Friedman (H&F), a premier global private equity firm, today announced that Aron Ain is joining the firm in an advisory role as an Operating Partner and member of the H&F CEO Council.
  • H&F led the take-private transactions for Kronos and Ultimate Software in 2007 and 2019, respectively, which subsequently merged to become UKG in 2020.
  • Aron Ain serves in an advisory role as an Operating Partner with Hellman & Friedman and member of the H&F CEO Council, where he brings more than 40 years of leadership experience.
  • David Simmons serves in an advisory role as an Operating Partner with Hellman & Friedman and member of the H&F CEO Council.

Cardiac Pacemakers Global Market Report 2022: Ukraine-Russia War Impact

Retrieved on: 
Tuesday, December 6, 2022

The cardiac pacemakers market is expected to grow to $4.91 billion in 2026 at a compound annual growth rate (CAGR) of 3.62%.

Key Points: 
  • The cardiac pacemakers market is expected to grow to $4.91 billion in 2026 at a compound annual growth rate (CAGR) of 3.62%.
  • The cardiac pacemakers market consists of sales of cardiac pacemaker devices by entities (organizations, sole traders, and partnerships) that are used to maintain the rhythm of heartbeats.
  • New innovations are a key trend in the cardiac pacemaker market.Major players are making innovations like leadless cardiac pacemakers to cater to the cardiac pacemaker market in a better way.
  • The cardiac pacemakers market research report is one of a series of new reports that provides cardiac pacemakers market statistics, including cardiac pacemakers industry global market size, regional shares, competitors with a cardiac pacemakers market share, detailed cardiac pacemakers market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac pacemakers industry.

Cordis promotes Alan Tsai as GM Greater China

Retrieved on: 
Monday, November 7, 2022

SHANGHAI, Nov. 7, 2022 /PRNewswire/ -- From November 1, 2022, Mr. Alan Tsai is promoted to the role of General Manager of Cordis Greater China.

Key Points: 
  • SHANGHAI, Nov. 7, 2022 /PRNewswire/ -- From November 1, 2022, Mr. Alan Tsai is promoted to the role of General Manager of Cordis Greater China.
  • "I am pleased that Alan is promoted as GM for Greater China.
  • Alan Tsai, GM of Cordis Greater China, said, "I am more than honored to be a member of our innovative Cordis team.
  • Adhereing to our spectacular brand value, I will lead the team of Cordis Greater China to enhance our existing product portfolio and accelerate localization in China.

Cordis Announces Acquisition of MedAlliance, Positioning Itself for Market Leadership in Drug-Eluting Balloon Technology

Retrieved on: 
Tuesday, October 18, 2022

By acquiring MedAlliance, Cordis has the potential to serve two million patients globally by 2027 with the SELUTION SLR (Sustained Limus Release) drug-eluting balloon.

Key Points: 
  • By acquiring MedAlliance, Cordis has the potential to serve two million patients globally by 2027 with the SELUTION SLR (Sustained Limus Release) drug-eluting balloon.
  • Cordis will immediately begin co-promotion of MedAlliance's SELUTION SLRdrug-eluting balloon in markets where it is commercially available.
  • "Nearly twenty years ago, Cordis introduced CYPHER, the first drug-eluting stent, transforming cardiovascular treatment for patients around the world," said Shar Matin, Cordis CEO.
  • "Today, we are furthering that legacy of innovation and market disruption with MedAlliance and the first MicroReservoir sirolimus drug-eluting balloon, SELUTION SLR."

Trial Lawyers Ben Martin, Laura Baughman Earn Texas Super Lawyers Honors for 2022

Retrieved on: 
Wednesday, September 21, 2022

DALLAS, Sept. 21, 2022 /PRNewswire/ -- The founding partners of Dallas-based Martin Baughman – veteran trial lawyers Ben Martin and Laura Baughman – have again earned recognition from Texas Super Lawyers for their skill at representing people harmed by dangerous products and catastrophic accidents.

Key Points: 
  • Martin Baughman founders recognized for protecting individuals from dangerous products, earning justice in catastrophic personal injury lawsuits
    DALLAS, Sept. 21, 2022 /PRNewswire/ -- The founding partners of Dallas-based Martin Baughman veteran trial lawyers Ben Martin and Laura Baughman have again earned recognition from Texas Super Lawyers for their skill at representing people harmed by dangerous products and catastrophic accidents.
  • This is the sixth year for Ms. Baughman and the 18th year for Mr. Martin to earn Super Lawyers honors.
  • Under their leadership, Martin Baughman was recognized by VerdictSearch and Texas Lawyer magazine for securing one of the largest verdicts in Texas in 2021.
  • The full listing appears in the October issue of Texas Monthly and the Texas edition of Super Lawyers magazine.